依达拉奉联合奥扎格雷钠治疗急性脑梗死42例

Therapeutic effect of Edaravone injection with Sodium Ozagrel on treatment of 42 cases with acute cerebral infarction

目的:观察依达拉奉联合奥扎格雷钠对急性脑梗死的疗效。方法:84例急性脑梗死病人,随机分为治疗组和对照组。治疗组用依达拉奉联合奥扎格雷钠治疗,依达拉奉注射液30mg,静滴,bid,奥扎格雷钠80mg,静滴,qd;对照组用奥扎格雷钠80mg,静滴,qd;14d为一疗程,连用两个疗程,其余常规治疗措施及方法均相同。结果:分别在治疗前,治疗后14,28d评估神经功能缺损程度、日常生活照顾能力、有效率比较;与治疗前比较,两组神经功能缺损评分均降低,但治疗组降低更明显,与对照组比较有统计学意义(P<0.01);治疗前后ADL评分比较均有改善,但治疗组改善更明显,与对照组比较有统计学意义(P<0.01);治疗后14,28d后治疗组和对照组总有效率分别为76.2%,57.1%,85.7%,69.0%;治疗组明显高于对照组(P<0.01)。结论:依达拉奉联合奥扎格雷钠治疗急性脑梗死疗效显著,无明显不良反应,值得推广应用。

Objective：To observe the efficacy of Edaravone injection with Sodium Ozagrel in treating acute cerebral infarction. Methods： 84 patients （pts） with cerebral infarction were divided randomly into 2 groups： The treatment group （n=42） were treated with Edaravone injection （30 mg a day） and Sodium Ozagrel （80 mg/d ） over 28 days; the control group （n=42） treated with Sodium Ozagrel （80 mg/d ） over 28 days.Results： The post-treatment neurological impair score（NIS） of 2 groups decreased significantly compared with that of pre-treatment, and it was more significant in experimental group whenever comparing with that of pre-treatment of itself or with that of control group at 14th and 28th day.（P〈0.01） .The effective rate in experimental group and control group was 76.2% and 57.1% at 14th day, 85.7% and 69% at 28th day,respectively,and the treatment group was higher than the control group statistically at 14th and 28th day （P〈0.01）. The ADL score is better in treatment group than that in the control group at 14th day and 28th day （P〈0.01）. Conclusion： Edaravone was safe and efficient in the treatment of acute cerebral infarction.